Advanced Human Imaging (AHI) AI Stock Analysis

• Market Cap: AU$20.52M
• Dividend Yield: N/A
• Average Volume (3M): 0.00
• Price to Earnings (P/E): ―
• Beta (1Y): -0.10
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: AU
• Employees: 19
• Sector: Healthcare
• Sector Strength: 40
• Industry: Software - Application
• EPS (TTM): N/A
• Shares Outstanding: 280,582,280
• 10 Day Avg. Volume: 0
• 30 Day Avg. Volume: 0
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: ―

The overall stock score for Advanced Human Imaging Ltd. is 37, reflecting significant financial weaknesses and valuation concerns. The company's persistent financial losses, high leverage, and negative cash flow position are major detractors. Additionally, the technical analysis shows bearish signals, with an overbought RSI suggesting potential price corrections. Despite a stable share price, the lack of profitability and dividend yield further weaken the stock's appeal.

Advanced Human Imaging Business Overview & Revenue Model

Company Description

Advanced Health Intelligence Ltd operates as a mobile application and technology development company in Australia and internationally. It develops and patents BodyScan, a proprietary measurement/dimensioning technology that enables end-user to check and assess body dimensions using a smartphone. The company also provides FaceScan for measuring vital signs, and risks associated with cardiovascular disease, heart attack, and stroke; and DermaScan, a dermatological scanner. It serves mobile health and telehealth, life and health insurance, fitness and wellness, and consumer apparel sectors. The company was formerly known as MyFiziq Limited and changed its name to Advanced Human Imaging Limited in March 2021. Advanced Human Imaging Limited was incorporated in 2014 and is based in South Perth, Australia.

How the Company Makes Money

Advanced Human Imaging makes money primarily through licensing its technology to other businesses and organizations. The company partners with healthcare providers, fitness companies, and wellness platforms, integrating its imaging solutions into their existing services and applications. These partnerships often involve subscription fees, integration fees, and usage-based charges, contributing to AHI's revenue. Additionally, AHI generates income from the direct sale of its applications to end users, who may pay for premium features or additional services. Strategic partnerships and collaborations with industry leaders also play a significant role in expanding AHI's market reach and revenue potential.

Advanced Human Imaging Financial Statement Overview

Summary

Advanced Human Imaging Ltd. shows substantial financial challenges, with negative profitability, high leverage, and cash flow difficulties across all financial statements. The income statement reflects persistent losses, the balance sheet indicates high debt levels relative to equity, and cash flow analysis shows inadequate cash generation from operations. These suggest significant financial distress, necessitating strategic improvements in revenue generation, cost management, and capital structure.

Income Statement

The company's income statement shows a troubling trend, with consistently negative gross profit margins and net income. The gross profit margin is negative due to costs exceeding revenue, and the net profit margin has been consistently negative as well. While there is revenue growth from the previous year, it is not sufficient to cover the losses or improve profitability. EBIT and EBITDA margins are also negative, indicating operational inefficiencies. Overall, the income statement reflects poor financial health and a need for significant improvement in revenue generation and cost management.

Balance Sheet

The balance sheet reveals a highly leveraged position with a debt-to-equity ratio that suggests substantial reliance on debt financing. The equity ratio is low, indicating that a smaller portion of the company's assets is financed by the owners. Return on equity is negative due to ongoing losses, further highlighting financial instability. While the company does have assets, the high level of liabilities poses risks to financial health and sustainability. The balance sheet reflects a need for better capital management and reduction of liabilities.

Cash Flow

Cash flow analysis shows negative operating cash flows, indicating the company is not generating enough cash from its core operations to sustain itself. The free cash flow is also negative, exacerbating concerns about liquidity and financial flexibility. The operating cash flow to net income ratio is unfavorable, as is the free cash flow to net income ratio, highlighting cash inefficiencies and the inability to convert earnings into cash. Despite inflows from financing activities, the overall cash flow position remains weak.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	2.68M	654.84K	257.60K	593.35K	139.86K
Gross Profit	-3.72M	-4.67M	-3.17M	-9.29M	-3.76M
EBITDA	-3.10M	-12.04M	-19.55M	-14.80M	-6.09M
Net Income	-4.15M	-12.83M	-20.08M	-14.06M	-5.40M
Balance Sheet
Total Assets	15.20M	8.91M	10.66M	5.42M	2.95M
Cash, Cash Equivalents and Short-Term Investments	25.76K	2.10M	6.01M	2.17M	627.30K
Total Debt	2.44M	1.80M	1.16M	2.32M	1.39M
Total Liabilities	11.92M	6.88M	2.11M	3.44M	2.49M
Stockholders Equity	1.75M	2.03M	8.56M	1.98M	462.51K
Cash Flow
Free Cash Flow	-4.75M	-7.43M	-9.95M	-4.13M	-2.76M
Operating Cash Flow	-4.75M	-7.37M	-9.86M	-4.10M	-2.70M
Investing Cash Flow	-95.64K	-669.26K	-3.38M	-3.44M	-84.68K
Financing Cash Flow	2.78M	4.17M	17.08M	9.09M	2.84M

Advanced Human Imaging Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Neutral
• RSI: Negative
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AHI, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.08, below the 50-day MA of 0.08, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Neutral momentum. The RSI at 100.00 is Negative, neither overbought nor oversold. The STOCH value of -50.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AHI.

Advanced Human Imaging Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.40B	-0.29	-44.86%	2.30%	24.10%	0.12%
PFM	49 Neutral	AU$14.43M	―	-25.95%	―	26.33%	31.67%
1CG	48 Neutral	AU$13.01M	―	-86.94%	―	26.58%	32.43%
AR9	48 Neutral	AU$71.24M	―	-45.31%	―	-28.80%	32.87%
AMX	45 Neutral	AU$20.90M	―	-24.21%	―	-11.35%	-49.13%
HTG	40 Neutral	AU$13.64M	―		―	0.82%	-58.82%
AHI	37 Underperform	AU$20.52M	―	-219.41%	―	―	―

Advanced Human Imaging Corporate Events

Advanced Health Intelligence Secures Funding for ASX Reinstatement and Growth

Advanced Health Intelligence Ltd has secured up to AUD $5.5 million in funding from Oakley Capital Partners, which will aid in its reinstatement to trading on the ASX and support its growth initiatives. The company is also pursuing additional funding to ensure a robust 12-month cash position and expects to receive up to AUD $3 million in non-dilutive capital through R&D grants. These financial strategies are part of AHI’s broader plan to enhance its balance sheet resilience and continue its commercial and strategic growth initiatives, despite its securities being suspended from trading.

Advanced Health Intelligence Announces Proposed Securities Issue

Advanced Health Intelligence Ltd has announced a proposed issue of securities, including 27.5 million options and 20 million ordinary fully paid shares, with an expected issue date of October 8, 2025. This move is part of the company’s strategy to raise capital, potentially enhancing its market position and providing additional resources for growth and development, which could have significant implications for stakeholders and the company’s future operations.

Advanced Health Intelligence Announces Proposed Securities Issue

Advanced Health Intelligence Ltd has announced a proposed issue of securities, with plans to issue up to 82,500,000 new securities, including options and ordinary shares. This move is aimed at raising capital to support the company’s operations and growth strategies. The issuance is set for October 8, 2025, and is expected to enhance the company’s market position by providing additional financial resources, potentially impacting stakeholders positively by bolstering the company’s capacity for innovation and expansion in the health technology sector.

Advanced Health Intelligence Announces Proposed Securities Issue

Advanced Health Intelligence Ltd has announced a proposed issue of 31,625,000 ordinary fully paid securities, with a planned issue date of April 1, 2027. This move is part of the company’s strategy to enhance its market positioning and operational capabilities, potentially impacting its stakeholders by increasing its financial resources and investment capacity.

Advanced Health Intelligence Secures AUD$5.5 Million Funding for ASX Reinstatement

Advanced Health Intelligence Ltd. has secured a funding commitment of up to AUD$5.5 million from Oakley Capital Partners to support its reinstatement to trading on the ASX and future growth initiatives. The funding will be structured through a private placement and convertible note facility, forming a crucial part of AHI’s broader capital strategy. Additionally, AHI is pursuing further funding opportunities, including a potential USD$6 million from strategic investors and up to AUD$3 million in non-dilutive R&D grants, to ensure a robust cash position and support its global growth strategy. The company has also implemented cost-reduction measures to enhance capital efficiency and is actively working towards meeting ASX compliance requirements for reinstatement.

Advanced Health Intelligence Expands Global Footprint and Secures Key Partnerships

Advanced Health Intelligence Ltd has had a commercially active quarter, marked by significant international expansion and technological advancements. The company launched the HIQOR platform in collaboration with Bearn LLC, secured its first insurance deployment with Unisure, and was listed on the Microsoft Azure Marketplace. AHI also received a U.S. patent for its smartphone-based disease risk assessment technology, reinforcing its leadership in mobile digital health. These developments position AHI for global scaling, with substantial funding initiatives and strategic partnerships supporting its growth and operational capacity.

Advanced Health Intelligence Aims for ASX and NASDAQ Compliance

Advanced Health Intelligence Ltd has announced its ongoing efforts to restore compliance with the ASX and NASDAQ exchanges following the delisting of its American Depositary Shares from NASDAQ due to shareholder equity deficiencies. The company is focused on reinstating its securities on the ASX by completing outstanding financial audits and governance submissions, which are prerequisites for any potential relisting on NASDAQ. AHI is actively seeking funding to meet these requirements and aims to demonstrate financial stability and governance readiness to regain its market position. The company has set a deadline to release its FY2024 Annual Report by 30 September 2025 to avoid removal from the ASX official list.

Advanced Health Intelligence Secures Extension for R&D Claim Submission

Advanced Health Intelligence Ltd has been granted a 31-day extension by AusIndustry to finalize its FY2024 R&D reimbursement submission, allowing the company to include international R&D expenditures in its claim. This extension is crucial for AHI as it anticipates receiving approximately AUD $1.1 million, which will support its operational execution during a critical phase of commercial expansion. The company’s consistent R&D reimbursements since 2017 highlight its commitment to innovation in the med-tech sector, while its expanding patent portfolio and global R&D activities reinforce its position as a leader in digital health. Additionally, AHI is pursuing an R&D Advance Facility for AUD $750,000, which, combined with the expected reimbursement, will strengthen its cash flow position with up to AUD $1,850,000 in non-dilutive capital.